Novavax Announces Us Fda Vrbpa Committee To Review Its Nvx-Cov2373 Covid-19 Vaccine

Novavax Announces Us Fda Vrbpa Committee To Review Its Nvx-Cov2373 Covid-19 Vaccine

By, Admin 2 May 2022

Novavax, Inc., A Biotechnology Company, Announced That The Us Food And Drug Administration'S (Fda) Vaccines And Related Biological Products Advisory Committee (Vrbpac) Will Review Nvx-Cov2373 Covid-19 Vaccine (Recombinant, Adjuvanted) For Active Immunization Against Sars-Cov-2 At A Meeting Scheduled For June 7, 2022. Vrbpac Reviews And Evaluates Data Regarding The Safety And Efficacy Of Vaccines And Related Biological Products That Are Intended For Use In The Prevention, Treatment, Or Diagnosis Of Human Diseases."We Continue To Hear From Physicians, Healthcare Organizations, And Consumers Who Are Anxiously Awaiting Another Vaccine Option. We Believe Our Vaccine, Built On A Well-Understood Protein-Based Vaccine Platform, Can Play A Part In Fulfilling This Need," Said Stanley C. Erck, President And Chief Executive Officer, Novavax. "We Look Forward To A Productive Vrbpac Meeting And Will Continue To Work With The Fda Throughout The Review Process."Novavax Submitted A Request To The Fda For Emergency Use Authorization (Eua) For Nvx-Cov2373 In January 2022 Based On The Totality Of Pre-Clinical, Clinical, And Manufacturing-Related Data Provided To The Agency.Nvx-Cov2373 Is A Protein-Based Vaccine Engineered From The Genetic Sequence Of The First Strain Of Sars-Cov-2, The Virus That Causes Covid-19 Disease. Nvx-Cov2373 Was Created Using Novavax' Recombinant Nanoparticle Technology To Generate Antigen Derived From The Coronavirus Spike (S) Protein And Is Formulated With Novavax' Patented Saponin-Based Matrix-M Adjuvant To Enhance The Immune Response And Stimulate High Levels Of Neutralizing Antibodies. Nvx-Cov2373 Contains Purified Protein Antigen And Can Neither Replicate, Nor Can It Cause Covid-19.Novavax' Covid-19 Vaccine Is Packaged As A Ready-To-Use Liquid Formulation In A Vial Containing Ten Doses. The Vaccination Regimen Calls For Two 0.5 Ml Doses (5 Mcg Antigen And 50 Mcg Matrix-M Adjuvant) Given Intramuscularly 21 Days Apart. The Vaccine Is Stored At 2

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!